#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2018 - 6

Possibilities of therapeutic manipulation of the gut microbiota

Czech version

Authors: Pavel Drastich 1;  Lukáš Bajer 1;  Miloslav Kverka 2,3
Authors‘ workplace: Klinika hepatogastroenterologie IKEM, Praha 1;  Mikrobiologický ústav AV ČR, v. v. i., Praha 2;  Ústav experimentální medicíny AV ČR, v. v. i., Praha 3
Published in: Vnitř Lék 2018; 64(6): 665-671
Category: Reviews

Overview

Human gut microbiota, complex ecosystem of microbes associated with human gut, is essential for the development of the host‘s immune system and many other physiological functions. Recently, numerous diseases and syndromes were associated with disruption of this ecosystem thus stressing its importance in maintaining the host‘s health. Growing evidence suggests that by manipulating the gut microbiota, some of these diseases could be treated or even prevented. These manipulations include changes in diet, use of probiotics, prebiotics, antibiotics and fecal microbiota transplantation (FMT). The successes in FMT treatment of recurrent infection of Clostridium difficile led recently to a great interest in extending this treatment modality to other diseases with proven disruption of gut microbiota, such as ulcerative colitis or metabolic syndrome.

Key words:

Clostridium difficile – dysbiosis – fecal microbial transplantation – microbiota – prebiotics – probiotics

Sources
  1. Gill SR, Pop M, Deboy RT et al. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312(5778): 1355–1359. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1124234>.
  2. Columpsi P, Sacchi P, Zuccaro V et al. Beyond the gut bacterial microbiota: The gut virome. J Med Virol 2016; 88(9): 1467–1472. Dostupné z DOI: <http://dx.doi.org/10.1002/jmv.24508>.
  3. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59–65. Dostupné z DOI: <http://dx.doi.org/10.1038/nature08821>.
  4. Hoffmann C, Dollive S, Grunberg S et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLoS One 2013; 8(6): e66019. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0066019>.
  5. Cebra JJ. Influences of microbiota on intestinal immune system development. Am J Clin Nutr 1999; 69(5): 1046S-1051S. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/69.5.1046s>.
  6. Kozakova H, Kolinska J, Lojda Z et al., Effect of bacterial monoassociation on brush-border enzyme activities in ex-germ-free piglets: comparison of commensal and pathogenic Escherichia coli strains. Microbes Infect 2006; 8(11): 2629–2639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.micinf.2006.07.008>.
  7. Tlaskalova-Hogenova H, Sterzl J, Stĕpánkova R et al. Development of immunological capacity under germfree and conventional conditions. Ann N Y Acad Sci 1983; 409: 96–113.
  8. [Human Microbiome Project Consortium]. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486(7402): 207–214. Dostupné z DOI: <http://dx.doi.org/10.1038/nature11234>.
  9. Costello EK, Lauber CL, Hamady M et al. Bacterial community variation in human body habitats across space and time. Science 2009; 326(5960): 1694–1697. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1177486>.
  10. Thaiss CA, Zeevi D, Levy M et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 2014; 159(3): 514–529. <http://dx.doi.org/10.1016/j.cell.2014.09.048>.
  11. Wang Y, Kuang Z, Yu Xet al. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock. Science 2017; 357(6354): 912–916. Dostupné z DOI: <http://dx.doi.org/10.1126/science.aan0677>.
  12. Jernberg C Löfmark S, Edlund C et al. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010; 156(pt 11): 3216–3223. Dostupné z DOI: <http://dx.doi.org/10.1099/mic.0.040618–0>
  13. Clemente JC, Ursell LK, Parfrey LW et al. The impact of the gut microbiota on human health: an integrative view. Cell 2012; 148(6): 1258–1270. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2012.01.035>.
  14. O‘Toole PW, Jeffery IB Gut microbiota and aging. Science 2015; 350(6265): 1214–1215. Dostupné z DOI: <http://dx.doi.org/10.1126/science.aac8469>.
  15. Palm NW, de Zoete MR, Cullen TW et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014; 158(5): 1000–1010. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cell.2014.08.006>.
  16. Shulzhenko N, Morgun A, Hsiao W et al. Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 2011; 17(12): 1585–1593. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.2505>.
  17. Bevins CL, Salzman NH. The potter‘s wheel: the host‘s role in sculpting its microbiota. Cell Mol Life Sci 2011; 68(22): 3675–3685. Dostupné z DOI: <http://dx.doi.org/10.1007/s00018–011–0830–3>.
  18. de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012; 70(Suppl 1): S45-S56. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1753–4887.2012.00505.x>.
  19. Mosca A, Leclerc M, Hugot JP. Gut Microbiota Diversity and Human Diseases: Should We Reintroduce Key Predators in Our Ecosystem? Front Microbiol 2016; 7: 455. Dostupné z DOI: <http://dx.doi.org/10.3389/fmicb.2016.00455>.
  20. McLean MH, Dieguez D Jr, Miller LM et al. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut 2015; 64(2): 332–341. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2014–308514>.
  21. Duboc H, Rajca S, Rainteau D et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013; 62(4): 531–539. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012–302578
  22. Wu N, Yang X, Zhang Ret al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 2013; 66(2): 462–470. Dostupné z DOI: <http://dx.doi.org/10.1007/s00248–013–0245–9>
  23. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13(10): 701–712. Dostupné z DOI: <http://dx.doi.org/10.1038/nrn3346>.
  24. Kverka M, Tlaskalova-Hogenova H. Intestinal Microbiota: Facts and Fiction. Dig Dis 2017; 35(1–2): 139–147. Dostupné z DOI: <http://dx.doi.org/10.1159/000449095>.
  25. Rampelli S, Schnorr SL, Consolandi C et al. Metagenome Sequencing of the Hadza Hunter-Gatherer Gut Microbiota. Curr Biol 2015; 25(13): 1682–1693. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cub.2015.04.055>.
  26. Bajer L, Kverka M, Kostovcik M et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 2017; 23(25): 4548–4558. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v23.i25.4548>.
  27. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018; 15(2): 111–128. Dostupné z DOI: <http://dx.doi.org/10.1038/nrgastro.2017.119>.
  28. Morgan XC, Huttenhower C. Meta‘omic analytic techniques for studying the intestinal microbiome. Gastroenterology 2014; 146(6): 1437–1448. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2014.01.049>.
  29. Tlaskalova-Hogenova H et al. Chapter 8 – Gnotobiology and the Study of Complex Interactions between the Intestinal Microbiota, Probiotics, and the Host. In: Mestecky J, Strober W, Russellet MW (eds)l.Mucosal Immunology. 4th ed. Academic Press: Boston 2015: 109–133. ISBN 978–0124158474.
  30. Stepankova R, Powrie F, Kofronova O et al., Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis 2007; 13(10): 1202–1211. Dostupné z DOI: <http://dx.doi.org/10.1002/ibd.20221>.
  31. Dalhoff A. Differences between bacteria grown in vitro and in vivo. J Antimicrob Chemother 1985; 15(Suppl A): 175–195.
  32. Marteyn B, Gazi A, Sansonetti P. Shigella: a model of virulence regulation in vivo. Gut Microbes 2012; 3(2): 104–120. Dostupné z DOI: <http://dx.doi.org/10.4161/gmic.19325>.
  33. De Filippo C, Cavalieri D, Di Paola M et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010; 107(33): 14691–14696. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1005963107>.
  34. Marchesi JR, Adams DH, Fava F et al. The gut microbiota and host health: a new clinical frontier. Gut 2016; 65(2): 330–339. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2015–309990>.
  35. Sabino J, Vieira-Silva S, Machiels K et al. Therapeutic Manipulation of the Gut Microbiota Through Diet to Reduce Intestinal Inflammation: Results from the FIT Trial. Gastroenterology 2017; 152(5 Suppl 1): S1. Dostupné z DOI: <https://doi.org/10.1016/S0016–5085(17)30385–2>.
  36. Nanayakkara WS, Skidmore PM, O‘Brien L et al. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol 2016; 9: 131–142. Dostupné z DOI: <http://dx.doi.org/10.2147/CEG.S86798>.
  37. Tlaskalova-Hogenova H, Vannucci L, Klimesova K et al. Microbiome and colorectal carcinoma: insights from germ-free and conventional animal models. Cancer J 2014; 20(3): 217–224. Dostupné z DOI: <http://dx.doi.org/10.1097/PPO.0000000000000052>.
  38. Gagniere J, Raisch J, Veziant J et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol 2016; 22(2): 501–518. Dostupné z DOI: <http://dx.doi.org/10.3748/wjg.v22.i2.501>.
  39. Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 5047480): 446–450. Dostupné z DOI: <http://dx.doi.org/10.1038/nature12721>. Erratum in Nature 2014; 506(7487): 254.
  40. Smith PM, Howitt MR, Panikov N et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341(6145): 569–573. Dostupné z DOI: <http://dx.doi.org/10.1126/science.1241165>.
  41. Perry RJ Peng L, Barry NA et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature 2016; 534(7606): 213–217. Dostupné z DOI: <http://dx.doi.org/10.1038/nature18309>.
  42. Vieira AT, Fukumori C, Ferreira CM. New insights into therapeutic strategies for gut microbiota modulation in inflammatory diseases. Clin Transl Immunology 2016; 5(6): e87. Dostupné z DOI: <http://dx.doi.org/10.1038/cti.2016.38>.
  43. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3(5): 442–448.
  44. Collins J, Robinson C, Danhof H et al. Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 2018; 553(7688): 291–294. Dostupné z DOI: <http://dx.doi.org/10.1038/nature25178>.
  45. Wong C, Harris PJ, Ferguson LR Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease. Int J Mol Sci; 2016; 17(6). pii: E919. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms17060919>.
  46. Daubioul CA, Horsmans Y, Lambert P et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study. Eur J Clin Nutr 2005; 59(5): 723–726. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ejcn.1602127>.
  47. Tran J, Wilson K, Plebanski M et al. Manipulating the microbiota to improve human health throughout life. Trans R Soc Trop Med Hyg 2017; 111(9): 379–381. Dostupné z DOI: <http://dx.doi.org/10.1093/trstmh/trx068>.
  48. FAO/WHO, Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. 2001, Food and Agriculture Organization of the United Nations and World Health Organization: Cordoba (Argentina).
  49. Reid G. Probiotics: definition, scope and mechanisms of action. Best Pract Res Clin Gastroenterol 2016; 30(1): 17–25. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bpg.2015.12.001>.
  50. Dinleyici EC, Kara A, Dalgic N et al. Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea. Benef Microbes 2015; 6(4): 415–421. Dostupné z DOI: <http://dx.doi.org/10.3920/BM2014.0086>.
  51. Wells JM, Rossi O, Meijerink M et al. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4607–4614. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1000092107>.
  52. Spinler JK, Sontakke A, Hollister EB et al. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 2014; 6(7): 1772–1789. Dostupné z DOI: <http://dx.doi.org/10.1093/gbe/evu137>.
  53. Zakostelska Z, Kverka M, Klimesova K et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 2011; 6(11): e27961. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0027961>.
  54. Quevrain E, Maubert MA, Michon C et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn‘s disease. Gut 2016; 65(3): 415–425. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2014–307649>.
  55. Fric P. Probiotics in gastroenterology. Z Gastroenterol. 2002; 40(3): 197–201. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2002–22328>.
  56. Hansen JJ, Sartor RB. Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. Curr Treat Options Gastroenterol 2015; 13(11): 105–120. Dostupné z DOI: <http://dx.doi.org/10.1007/s11938–014–0042–7).
  57. Bar F, Von Koschitzky H, Roblick U et al. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21(5): 559–566. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2982.2008.01258.x>.
  58. Mondel M, Schroeder BO, Zimmermann K et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009; 2(2): 166–172. <http://dx.doi.org/10.1038/mi.2008.77>.
  59. Cicenia A Santangelo F, Gambardella L et al. Protective Role of Postbiotic Mediators Secreted by Lactobacillus rhamnosus GG Versus Lipopolysaccharide-induced Damage in Human Colonic Smooth Muscle Cells. J Clin Gastroenterol 2016; 50(Suppl 2): Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13–15, 2015: S140-S144. Dostupné z DOI: <http://dx.doi.org/10.1097/MCG.0000000000000681>.
  60. Rousseaux C, Thuru X, Gelot A et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13(1): 35–37. Dostupné z DOI: <http://dx.doi.org/10.1038/nm1521>.
  61. Alisi A, Bedogni G, Baviera G et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2014; 39(11): 1276–1285. Dostupné z DOI: <http://dx.doi.org/10.1111/apt.12758>.
  62. Braat H, Rottiers P, Hommes DW et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn‘s disease. Clin Gastroenterol Hepatol 2006; 4(6): 754–759. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2006.03.028>.
  63. Menees SB, Maneerattannaporn M, Kim HM et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107(1): 28–35; quiz 36. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2011.355>.
  64. Reijnders D, Goossens GH, Hermes GD et al. Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. Cell Metab 2016; 24(1): 63–74. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2016.06.016>.
  65. Zhang F, Luo W, Shi Y et al. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012; 107: 1755; author reply p.1755–6. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2012.251>.
  66. Eiseman B, Silen W, Bascom GS et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44(5): 854–859.
  67. van Nood E, Vrieze A, Nieuwdorp M,et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368(5): 407–415. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1205037>.
  68. Březina J Bajer L, Špičák J et al. Fekální mikrobiální transplantace u idiopatických střevních zánětů. Gastroent Hepatol 2016; 70(1): 51–56.
Labels
Diabetology Endocrinology Internal medicine
Current trends in the diagnosis and treatment of gastroesophageal reflux disease
Therapy for peptic ulcer disease
History of celiac disease
Celiac disease in 2018
Diagnosis of gastrointestinal motility disorders
Diverticular disease: diagnosis and treatment
Familial adenomatous polyposis: complex patient management
Conventional and biological therapy for inflammatory bowel disease
The IBD outpatient care in the clinical practice
PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis
Prokinetics and their use in gastroenterology
Colorectal cancer screening
Therapeutic digestive endoscopy I
Therapeutic digestive endoscopy II
Article was published in

Internal Medicine

Issue 6
2018 Issue 6
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#